Key TakeawaysRoche announced strong early stage data from its weight-loss drug CT-996.The once-daily pill delivered placebo-adjusted mean weight loss of 6.1% in obesity patients without diabetes.CT-996 represent possible competition to popular weight-loss drugs Novo Nordisk's Wegovy and Eli Lilly's Zepbound. A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, sending shares of rival GLP-1 developers Eli Lilly and Company (LLY) and Nov ...

ToplineShares of Swiss pharma giant Roche climbed Wednesday after it reported promising results for an experimental weight loss pill, part of a cohort of hopeful competitors racing to challenge Novo Nordisk and Eli Lilly in the burgeoning diabetes and obesity drug market amid growing evidence the drugs can treat many other health conditions like kidney disease and sleep apnea.Roche said it had promising results from an ongoing trial for its obesity pill and would progress to ... [+] mid-stage trials.SOPA Im ...

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market.Roche shares jumped in early deals and were trading 5.87% higher as of 11:17 a.m. London time.Shares of Wegovy-maker Novo Nordisk fell 3.77%, while Zepbound produc ...

After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001)1 Pharmacokinetic data supports a once-daily oral dosing regimen for CT-9961The safety and tolerability profile was consistent with other oral GLP-1 receptor agonists and no unexpected safety signals were observed1 Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial f ...

文章核心观点 - 罗氏控股公司(RHHBY)近期获得了其Accu-Chek SmartGuide持续性葡萄糖监测(CGM)解决方案的CE认证[1][2] - 该CGM解决方案可为18岁以上1型和2型糖尿病患者提供实时葡萄糖数据,有助于预防低血糖等关键问题[3][4][5][6] - Accu-Chek SmartGuide CGM解决方案包括传感器、应用程序和预测应用程序,可为医疗专业人员提供更全面的患者数据,支持个性化治疗[7][8] 行业概况 - 根据MarketsandMarkets的报告,全球数字糖尿病管理市场预计将从2023年的189亿美元增长到2028年的358亿美元,复合年增长率为13.6%[9][10] - 该市场增长得益于糖尿病护理解决方案的不断升级以及连接设备和云端解决方案的广泛应用[10] 公司动态 - 罗氏控股最近获得FDA批准其Vabysmo 6.0 mg单剂量预充注射器,用于治疗湿性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞后黄斑水肿[11] - 过去6个月,RHHBY股价下跌0.9%[12] - 目前RHHBY评级为持有(Zacks Rank 3),同行业中DaVita、Stryker和Universal Health Services表现较好[13][14][15][16][17]

文章核心观点 - 公司与罗氏达成合作,利用公司的REMaster™平台发现新药 [1][2] - 公司有资格获得高达10亿美元的里程碑付款和版税 [1][2] - 公司的REMaster平台可以识别新的可药物化的RNA处理机制 [2] 公司概况 - 公司是一家处于临床阶段的生物技术公司,专注于开发小分子疗法来调节RNA处理,解决疾病根源 [3] - 公司的REMaster技术平台可以识别RNA处理模式,并利用这些知识来调节基因表达 [3] - 公司的创新疗法有潜力改变基因的读取方式,从而纠正、增强或消除基因信息,解决疾病根源 [3] 合作协议 - 根据2024年1月宣布的协议,公司获得了3000万美元的预付款和一笔近期里程碑付款 [2] - 公司有资格获得高达10亿美元的临床、商业和销售里程碑付款,以及分级的版税 [2] - 作为交换,罗氏将获得特定靶点的独家权利,公司将负责发现和临床前活动,罗氏将负责后续的开发和商业化 [2]

The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur.The solution is set to launch in selected European markets in the coming months. Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received t ...

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections that are standard of care for nAMD, which impacts 20 million people worldwide and can cause blindness if left untreatedBy continuously delivering medicine to the eye through a refillable implant, Susvimo is the first and only approved nAMD treatment shown to maintain vision with two refills a year Basel, 08 July 202 ...

Roche (RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a label expansion of ophthalmology drug Vabysmo (faricimab). The CHMP gave a positive opinion for the label extension of Vabysmo for a third indication — treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO). The European Commission is expected to give a final decision shortly. The positive CHMP opinion is based on full 72-week data from t ...

Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to aflibercept If approved, Vabysmo would be the first and only bispecific antibody treatment available for the nearly one million people with RVO in the European Union Vabysmo is already approved in the US and Japan for RVO and in more than 95 countries around the world for people living with nAMD and DME Basel, 28 June ...